These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38729076)

  • 21. Cytotoxic-T-lymphocyte-mediated elimination of target cells transduced with engineered adeno-associated virus type 2 vector in vivo.
    Li C; Hirsch M; DiPrimio N; Asokan A; Goudy K; Tisch R; Samulski RJ
    J Virol; 2009 Jul; 83(13):6817-24. PubMed ID: 19369348
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Type 1 and type 2 CD8+ effector T cell subpopulations promote long-term tumor immunity and protection to progressively growing tumor.
    Dobrzanski MJ; Reome JB; Dutton RW
    J Immunol; 2000 Jan; 164(2):916-25. PubMed ID: 10623840
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CAF05: cationic liposomes that incorporate synthetic cord factor and poly(I:C) induce CTL immunity and reduce tumor burden in mice.
    Hansen J; Lindenstrøm T; Lindberg-Levin J; Aagaard C; Andersen P; Agger EM
    Cancer Immunol Immunother; 2012 Jun; 61(6):893-903. PubMed ID: 22095092
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Anti-metastatic effect of vascular endothelial growth factor receptor 2 extracellular domain gene-modified dendritic cell vaccination in murine model with experimental pulmonary metastasis].
    Pan JP; Weng YS; Wu QQ
    Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):646-9. PubMed ID: 17274366
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytotoxic T lymphocytes generated by short-term in vitro TCR stimulation in the presence of IL-4 are therapeutically effective against B16 melanoma.
    Chang ML; Chen YT; Su YC; Kung JT
    J Biomed Sci; 2003; 10(6 Pt 1):644-50. PubMed ID: 14576467
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of clinical outcomes between carbon ion radiotherapy and X-ray radiotherapy for reirradiation in locoregional recurrence of rectal cancer.
    Chung SY; Takiyama H; Kang JH; Chang JS; Min BS; Tsuji H; Yamada S; Koom WS
    Sci Rep; 2022 Feb; 12(1):1845. PubMed ID: 35115612
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Archaeosomes as self-adjuvanting delivery systems for cancer vaccines.
    Krishnan L; Dennis Sprott G;
    J Drug Target; 2003; 11(8-10):515-24. PubMed ID: 15203920
    [TBL] [Abstract][Full Text] [Related]  

  • 28. T helper cells in cytotoxic T lymphocyte development: role of L3T4(+)-dependent and -independent T helper cell pathways in virus-specific and alloreactive cytotoxic T lymphocyte responses.
    Ciavarra RP
    Cell Immunol; 1990 Feb; 125(2):363-79. PubMed ID: 2153464
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transgenic 4-1BBL-engineered vaccine stimulates potent Gag-specific therapeutic and long-term immunity via increased priming of CD44(+)CD62L(high) IL-7R(+) CTLs with up- and downregulation of anti- and pro-apoptosis genes.
    Wang R; Freywald A; Chen Y; Xu J; Tan X; Xiang J
    Cell Mol Immunol; 2015 Jul; 12(4):456-65. PubMed ID: 25195511
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CD4(+) T cell-released exosomes inhibit CD8(+) cytotoxic T-lymphocyte responses and antitumor immunity.
    Zhang H; Xie Y; Li W; Chibbar R; Xiong S; Xiang J
    Cell Mol Immunol; 2011 Jan; 8(1):23-30. PubMed ID: 21200381
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Radiotherapy-induced anti-tumor immunity contributes to the therapeutic efficacy of irradiation and can be augmented by CTLA-4 blockade in a mouse model.
    Yoshimoto Y; Suzuki Y; Mimura K; Ando K; Oike T; Sato H; Okonogi N; Maruyama T; Izawa S; Noda SE; Fujii H; Kono K; Nakano T
    PLoS One; 2014; 9(3):e92572. PubMed ID: 24686897
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enhanced suppression of polyclonal CD8
    Mu C; Zhang X; Wang L; Xu A; Ahmed KA; Pang X; Chibbar R; Freywald A; Huang J; Zhu Y; Xiang J
    J Leukoc Biol; 2017 May; 101(5):1221-1231. PubMed ID: 28096300
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An agonistic anti-Toll-like receptor 4 monoclonal antibody as an effective adjuvant for cancer immunotherapy.
    Tsukamoto H; Kubota K; Shichiku A; Maekawa M; Mano N; Yagita H; Ohta S; Tomioka Y
    Immunology; 2019 Oct; 158(2):136-149. PubMed ID: 31515801
    [TBL] [Abstract][Full Text] [Related]  

  • 34. NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation.
    Xu D; Gu P; Pan PY; Li Q; Sato AI; Chen SH
    Int J Cancer; 2004 Apr; 109(4):499-506. PubMed ID: 14991570
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antigen delivery by alpha(2)-macroglobulin enhances the cytotoxic T lymphocyte response.
    Bowers EV; Horvath JJ; Bond JE; Cianciolo GJ; Pizzo SV
    J Leukoc Biol; 2009 Nov; 86(5):1259-68. PubMed ID: 19652028
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New generation of DNA-based immunotherapy induces a potent immune response and increases the survival in different tumor models.
    Lopes A; Bastiancich C; Bausart M; Ligot S; Lambricht L; Vanvarenberg K; Ucakar B; Gallez B; Préat V; Vandermeulen G
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33795383
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intradermal DNA electroporation induces survivin-specific CTLs, suppresses angiogenesis and confers protection against mouse melanoma.
    Lladser A; Ljungberg K; Tufvesson H; Tazzari M; Roos AK; Quest AF; Kiessling R
    Cancer Immunol Immunother; 2010 Jan; 59(1):81-92. PubMed ID: 19526360
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transgene IL-6 enhances DC-stimulated CTL responses by counteracting CD4+25+Foxp3+ regulatory T cell suppression via IL-6-induced Foxp3 downregulation.
    Bhanumathy KK; Zhang B; Ahmed KA; Qureshi M; Xie Y; Tao M; Tan X; Xiang J
    Int J Mol Sci; 2014 Mar; 15(4):5508-21. PubMed ID: 24690994
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cx43-Gap Junctions Accumulate at the Cytotoxic Immunological Synapse Enabling Cytotoxic T Lymphocyte Melanoma Cell Killing.
    Hofmann F; Navarrete M; Álvarez J; Guerrero I; Gleisner MA; Tittarelli A; Salazar-Onfray F
    Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31547237
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An indispensable role of type-1 IFNs for inducing CTL-mediated complete eradication of established tumor tissue by CpG-liposome co-encapsulated with model tumor antigen.
    Wakita D; Chamoto K; Zhang Y; Narita Y; Noguchi D; Ohnishi H; Iguchi T; Sakai T; Ikeda H; Nishimura T
    Int Immunol; 2006 Mar; 18(3):425-34. PubMed ID: 16415100
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.